Healthcare
Design Therapeutics, Inc.(DSGN)
Live Price
Offline$12.44
+4.27% today
1Y Change
+247.85%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $840.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -38.6%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Design Therapeutics, Inc. (DSGN) is a Healthcare stock with a market cap of $840.00M and listed on NASDAQ. The stock last traded around $12.44 and up 247.8% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -38.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -38.6%, free cash flow -25.6% with operating margin 0.0% and ROIC -35.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DSGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -38.6%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +9.8% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -3.1% | +7.4% | -26.0% |
2026 Mar 9, 2026 | +28.9% | -3.7% | +6.0% | +17.8% |
2025 Nov 5, 2025 | +11.8% | +4.9% | +16.2% | +49.9% |
Benchmark Edge
DSGN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DSGN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DSGN Max Drawdown
-35.59%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DSGN and SPY.
Company Overview
Design Therapeutics, Inc.
NASDAQ Global Select
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
- Leadership
- Pratik Shah
- IPO Date
- Mar 29, 2021
- Employees
- 56
- Street Address
- 6005 Hidden Valley Road
- Mailing
- Carlsbad, CA, 92011
- Region
- Carlsbad, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 293 4900
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 3.8
Growth
- Revenue
- 0.0%
- EPS
- -38.6%
- Free Cash Flow
- -25.6%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -33.1%
- ROIC
- -35.7%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 22.28
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.